


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A compound of the formula I:



(I)

or a pharmaceutically acceptable salt thereof;

wherein X and Y are independently selected from the group consisting of O, CF₂, CH₂, and CHF;

wherein A is P(O)OH;

R₂ is selected from the group consisting of H, OH, C₁-C₂₅ alkyloxy, C₆-C₁₀ aryloxy, C₃-C₈ cycloalkyloxy, C₃-C₈ cycloalkyl C₁-C₆ alkoxy, C₂-C₂₂ alkenyloxy, C₃-C₈ cycloalkenyloxy, C₇-C₃₂ aralkyloxy, C₇-C₃₂ alkylaryloxy, C₉-C₃₂ aralkenyloxy, and C₉-C₃₂ alkenylaryloxy;


R₃-R₆ are independently selected from the group consisting of H and OH; and

R₁ and R₇ are independently selected from the group consisting of C₁-C₂₅ alkyl, C₆-C₁₀ aryl, C₃-C₈ cycloalkyl, C₂-C₂₂ alkenyl, C₃-C₈ cycloalkenyl, C₇-C₃₂ aralkyl, C₇-C₃₂ alkylaryl, C₉-C₃₂ aralkenyl, and C₉-C₃₂ alkenylaryl;

with the provisos that (i) when X is O, Y is O or CH₂, and R₃ is H, at least one of R₂ and R₄-R₆ is not OH; (ii) all of R₂-R₆ are not simultaneously H; (iii) R₅ and R₄ are not simultaneously H; [[and]] (iv) R₂, R₃, R₅, and R₆ are not simultaneously OH or H; and (v) when X and Y are O, R₁ is C₁₈H₃₇, and only one of R₂ and R₆ is OCH₃, then R₃ and R₅ are not simultaneously OH.


2. (Canceled)

3. (Previously Presented) The compound of claim 1, which has the formula Ia:



(Ia).

4. (Previously Presented) The compound of claim 1, which has the formula Ib:



(Ib).

5. (Currently Amended) The compound of claim 1, wherein X and Y are O.

6. (Previously Presented) The compound of claim 1, wherein R₁ is a C₁-C₂₅ alkyl.

7. (Previously Presented) The compound of claim 1, wherein R₁ is a C₁₀-C₂₅ alkyl.

8. (Previously Presented) The compound of claim 1, wherein R₁ is a C₁₅-C₂₀ alkyl.

9. (Previously Presented) The compound of claim 1, wherein R₁ is a C₁₈ alkyl.

10. (Previously Presented) The compound of claim 1, wherein R₇ is a C₁-C₂₅ alkyl.

11. (Previously Presented) The compound of claim 1, wherein R₇ is a C₁-C₁₅ alkyl.


12. (Previously Presented) The compound of claim 1, wherein R₇ is a C₁-C₅ alkyl.

13. (Previously Presented) The compound of claim 1, wherein R₇ is methyl.

14. (Previously Presented) The compound of claim 1, wherein R₂ is C₁-C₂₅ alkyloxy.

15. (Previously Presented) The compound of claim 1, wherein R₂ is C₁-C₁₅ alkyloxy.

16. (Previously Presented) The compound of claim 1, wherein R_2 is C_1 - C_5 alkyloxy.
17. (Previously Presented) The compound of claim 1, wherein R_2 is methoxy.
18. (Previously Presented) The compound of claim 1, wherein R_2 is C_7 - C_{32} aralkyloxy.
19. (Previously Presented) The compound of claim 1, wherein R_2 is cyclohexylmethoxy.
20. (Previously Presented) The compound of claim 1, wherein R_2 is H.
21. (Previously Presented) The compound of claim 1, wherein R_3 is H.
22. (Previously Presented) The compound of claim 1, wherein R_4 is H.
23. (Previously Presented) The compound of claim 1, wherein R_5 is H.
24. (Previously Presented) The compound of claim 1, wherein R_6 is H.
25. (Previously Presented) The compound of claim 1, wherein R_2 and R_3 are H.
26. (Previously Presented) The compound of claim 1, wherein R_3 and R_4 are H.
27. (Previously Presented) The compound of claim 1, wherein R_5 and R_6 are H.
28. (Original) The compound of claim 3, wherein X and Y are O, R_1 is $C_{18}H_{37}$, and R_7 is methyl.
29. (Original) The compound of claim 28, wherein R_2 is methoxy, R_3 is H, and R_4 - R_6 are OH.
30. (Original) The compound of claim 28, wherein R_2 - R_3 are H and R_4 - R_6 are OH.
31. (Currently Amended) ~~The compound of claim 28,~~ A compound of the formula:




wherein X and Y are O, R₁ is C₁₈H₃₇, and R₇ is methyl; and R₂-R₃ and R₅-R₆ are OH and R₄ is H.

32. (Original) The compound of claim 28, wherein R₂ is i-butyloxy, R₃ is H, and R₄-R₆ are OH.

33. (Original) The compound of claim 28, wherein R₂ is cyclohexylmethoxy, R₃ is H, and R₄-R₆ are OH.

34. (Currently Amended) ~~The compound of claim 28;~~ A compound of the formula:



wherein X and Y are O, R₁ is C₁₈H₃₇, R₇ is methyl, R₂-R₃ and R₆ are OH, and R₄-R₅ are H.

35. (Original) The compound of claim 28, wherein R₂-R₄ and R₆ are OH and R₅ is H.

36. (Original) The compound of claim 28, wherein R₂, R₄, and R₆ are OH and R₃ and R₅ are H.

37. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

38. (Previously Presented) A method of inhibiting activation of the serine/threonine kinase Akt or decreasing phosphorylation in a tumor cell of an animal comprising administering to the animal an effective amount of a compound of claim 1.

39-52. (Canceled)

53. (Previously Presented) A method of increasing apoptosis of a cell comprising contacting the cell with a compound of claim 1.

54. (Previously Presented) A method for inhibiting PH domain binding comprising exposing a material containing an PH domain to a compound of claim 1.


55. (Previously Presented) A method for determining the presence of a PH domain in a material comprising:

- (a) exposing a sample of said material to a PH domain binding compound and obtaining a first binding result;
- (b) exposing another sample of said material to a compound of claim 1 and obtaining a second binding result; and
- (c) comparing the first and second binding results to determine whether a PH domain is present in the material.

56. (Currently Amended) A method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound of claim 1, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, ovarian cancer, colorectal cancer, and brain cancer.

57. (Canceled)

58. (Currently Amended) A compound of the formula I:



or a pharmaceutically acceptable salt thereof;

wherein X and Y are independently selected from the group consisting of O, CF₂, CH₂, and CHF;

wherein A is P(O)OH; ~~independently selected from the group consisting of P(O)OH, CHCOOH, and C(COOH)₂~~;

R₂ is selected from the group consisting of C₁-C₂₅ alkyloxy, cyclohexylmethoxy, and C₇-C₃₂ aralkyloxy;

R₃-R₆ are independently selected from the group consisting of H, OH, isosteres of OH; and R₁ and R₇ are independently selected from the group consisting of C₁-C₂₅ alkyl, C₆-C₁₀ aryl, C₃-C₈ cycloalkyl, C₂-C₂₂ alkenyl, C₃-C₈ cycloalkenyl, C₇-C₃₂ aralkyl, C₇-C₃₂ alkylaryl, C₉-C₃₂ aralkenyl, and C₉-C₃₂ alkenylaryl;

with the provisos that (i) when X is O, Y is O or CH₂, and R₃ is H, at least one of R₂ and R₄-R₆ is not OH; (ii) ~~when A is CHCOOH or C(COOH)₂, X and Y cannot be simultaneously O;~~ and (iii) all of R₂-R₆ are not simultaneously H; and when X and Y are O, R₁ is C₁₈H₃₇, and only one of R₂ and R₆ is OCH₃, then R₃ and R₅ are not simultaneously OH.


59. (Previously Presented) The compound of claim 58, wherein R₂ is C₁-C₂₅ alkyloxy.

60. (Previously Presented) The compound of claim 58, wherein R₂ is C₇-C₃₂ aralkyloxy.

61. (Previously Presented) The compound of claim 58, wherein R₂ is cyclohexylmethoxy.

62. (Previously Presented) The compound of claim 58, wherein R₃ and R₄ are H.

63. (Previously Presented) The compound of claim 58, which has the formula Ia:



(Ia)

wherein X and Y are O, R₁ is C₁₈H₃₇, R₇ is methyl, R₂ is methoxy, R₃ is H, and R₄-R₆ are OH.

64. (Previously Presented) A method of increasing apoptosis of a cell comprising contacting the cell with a compound of claim 58.

65. (Previously Presented) A method for inhibiting PH domain binding comprising exposing a material containing an PH domain to a compound of claim 58.

66. (Previously Presented) A pharmaceutical composition comprising a compound of claim 58 and a pharmaceutically acceptable carrier.

67. (Currently Amended) A method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound of claim 58, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, ovarian cancer, colorectal cancer, and brain cancer.

68. (Previously Presented) A method of inhibiting activation of the serine/threonine kinase Akt or decreasing phosphorylation in a tumor cell of an animal comprising administering to the animal an effective amount of a compound of claim 58.

69. (Canceled)

70. (New) A pharmaceutical composition comprising a compound of claim 31 and a pharmaceutically acceptable carrier.

71. (New) A pharmaceutical composition comprising a compound of claim 34 and a pharmaceutically acceptable carrier.